Nana-Ama A.S. Anang

Statistics

Publications

Citations

3.1K

H-Index

Active since

2017

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Parker Institute for Cancer Immunotherapy

Kettering University

Columbia University

University of Pennsylvania

Nana-Ama A.S. Anang is an author at The University of Texas MD Anderson Cancer Center specializing in checkpoint inhibitor therapy, cancer immunotherapy, and immunology.

ORCID

Publications per year

2017–2025

Publications

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

Spencer C. Wei, Jacob Levine, Alexandria P. Cogdill et al. · Cell · 2017 · 1.3K citations · Full text

Medicine, Cancer Biology, Oncology +14

Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response

Christine N. Spencer, Jennifer L. McQuade, Vancheswaran Gopalakrishnan et al. · Science · 2021 · 879 citations · Full text

Life Sciences, Immunology, Oncology +17

Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

Spencer C. Wei, Nana-Ama A.S. Anang, Roshan Sharma et al. · Proceedings of the National Academy of Sciences · 2019 · 361 citations · Full text

Life Sciences, Immunology, Oncology +17

A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention

Spencer C. Wei, Wouter C. Meijers, Margaret L. Axelrod et al. · Cancer Discovery · 2020 · 272 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC

Robert Saddawi‐Konefka, Aoife O’Farrell, Farhoud Faraji et al. · Nature Communications · 2022 · 174 citations · Full text

Life Sciences, Immunology, Oncology +17

1–5 of 7